Association of MCP‐1 promotor polymorphism with disease severity of Crimean‐Congo hemorrhagic fever

Abstract

Crimean‐Congo hemorrhagic fever (CCHF) is a thick‐borne viral zoonotic disease. The pathogenesis and the reasons why cases have a mild or severe course in CCHF have not yet been explained. In this study, we investigated the relationship between promoter ‐2518 A/G single‐nucleotide polymorphism (SNP) of the MCP‐1 gene and the clinical course of CCHF. The MCP‐1‐2518 A/G SNP (rs1024611) frequency was examined in 128 virologically/serologically confirmed CCHF patients and 181 healthy controls by using the PCR‐RFLP method. When CCHF patients and controls were compared, no significant difference was found between genotype distributions and allele frequencies of the ‐2518 A/G SNP of MCP‐1 gene (P > .05). Compared to the AA genotype, both AG (P = .016; OR = 2.57) and GG genotype (P = .039; OR = 3.43) were found with significantly higher frequencies in mild/moderate cases than in severe cases. Compared to the AG + GG genotype, AA showed a significant risk for severe CCHF (60.0% vs 38.4%, P = .02; OR = 2.41). In contrast, the AG genotype showed a significant protective effect against severe disease compared to AA + GG genotype (29.1% vs 47.9%, P = .013; OR = 2.58). Compared to mild/moderate cases, the A allele was found to be significantly higher in severe cases (0.745 vs 0.623, P = .039; OR = 1.77). However, no significant relationship was found between fatal and nonfatal cases in terms of genotype or allele frequencies (P > .05). In conclusion, both ‐2518 AA genotype and A allele of MCP‐1 were associated with disease severity, and the AG genotype had a protective effect against a severe disease course in CCHF patients.

The Relation Between Serum Alpha Defensin-1 Levels with Clinical Course and Prognosis in Crimean-Congo Hemorrhagic Fever

“…Patients were divided into mild/moderate and severe on the basis of clinical severity. The defined criteria for patients were the presence of at least one; leukocyte count ≥10,000/mm 3 , thrombocyte count ≤20,000/mm 3 , aspartate aminotransferase (AST) ≥200 IU/L, alanine aminotransferase (ALT) ≥150 IU/L, activated partial thromboplastin time (aPTT) ≥60 sec, or fibrinogen ≤110 µg/dl in the first 5 days after onset of clinical symptoms as a severe case and absence of any of these as a mild/moderate case (10). Thirty-eight healthy volunteers were enrolled as the control group.…”

Association of IL‐32 rs28372698 polymorphism with active chronic HBV infection

“…The host genetic background plays a very important role in the pathogenesis and eventual outcome of all kinds of diseases 3 . It has been reported that some genes could affect the pathogenesis and outcome of infectious diseases 4–6 . Interleukin‐32 (IL‐32), which is a multifunctional inflammatory cytokine, is related to the pathogenesis of many diseases, such as inflammatory bowel disease, 7 HIV infection, 8 and rheumatoid arthritis 9 …”

“…3 It has been reported that some genes could affect the pathogenesis and outcome of infectious diseases. [4][5][6] Interleukin-32 (IL-32), which is a multifunctional inflammatory cytokine, is related to the pathogenesis of many diseases, such as inflammatory bowel disease, 7 HIV infection, 8 and rheumatoid arthritis. 9 The IL-32 gene, located on chromosome 16 p 13.3, contains 8 exons and 6 isoforms: IL-32α, β, γ, δ, ε and ζ.…”